February 19, 2010
FDA unveils risk-management plan for Amgen anti-anemia drugs
Physicians who want to prescribe Amgen Inc.’s anti-anemia drugs for cancer patients will have to register and undergo special training under a risk-management plan unveiled Tuesday by the Food and Drug Administration. Amgen also will require physicians to collect signed statements from patients attesting that they have been informed about the dangers of the drugsā¦ […]
Tags: anti-anemia drugs